/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Our company is a targeted healthcare holding company dedicated to acquiring and building middle-market niche healthcare clinics, primarily in orthopedics, spine care, and pain management. Our partnership-driven culture emphasizes service excellence, teamwork, accountability, and performance.
$0.20
+$0.00 (+0.00%)
Price from 2 days ago
Operating margin is thin at 9.54%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue up 39.5% YoY with margins expanding 11.9pp.
Negative free cash flow of -$3M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$10M
▲ +39.5% YoY
Net Income (TTM)
-$9M
▼ -66.7% YoY
Op. Margin
-10.86%
▲ +11.9pp YoY
ROIC
-5.55%
▲ +6.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$2M
▼ -3.2% YoY
Op. Cash Flow (TTM)
-$2M
▼ -3.2% YoY
Net Debt
$23M
Cash & Equiv.
$218K
5Y CAGR: +27.3%
Continue Research
SourceComputed from the 10-Q filed 12 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 13 Aug 2026. How this is calculated.
Price from market data, last close as of 31 Aug 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Cardiff Lexington (CDIX)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Cardiff Lexington scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Cardiff Lexington scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -10.9% operating margin and a -5.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh CDIX's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.